• Novo Nordisk (NYSE:NVO) has received an FDA National Priority Voucher tied to a higher dose of its obesity drug Wegovy.
• This is the fourth such voucher granted for the higher dose version, marking another key regulatory step for the product.
• The decision comes as the FDA prepares a June public meeting to review and discuss the controversial priority voucher program.
• Lawmakers have called for more transparency around how these vouchers are awarded and used, which could influence future regulatory processes.

Novo Nordisk enters this phase of the regulatory discussion with a current share price of $36.04. The stock has seen a 31.2% decline year to date and a 47.0% decline over the past year, while the 5 year return is 12.1%. For…